[Treatment of localized nasal NK/T-cell lymphoma].
Yamaguchi
Motoko
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D006037:Glyoxal / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D054391:Lymphoma, Extranodal NK-T-Cell / Q000628:therapy*; D036102:Peripheral Blood Stem Cell Transplantation; D011238:Prednimustine / Q000008:administration & dosage; D011239:Prednisolone / Q000008:administration & dosage; D011379:Prognosis; D011878:Radiotherapy / Q000379:methods; D014750:Vincristine / Q000008:administration & dosage
D006037:Glyoxal; D014750:Vincristine; D005047:Etoposide; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide; D011238:Prednimustine; D011239:Prednisolone; D016190:Carboplatin; D007069:Ifosfamide